Piper Jaffray Upgrades Seattle Genetics (SGEN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Seattle Genetics Reports Third Quarter 2015 Financial Results
October 29, 2015 4:02 PM EDT-Total Third Quarter 2015 Revenues of $84.1 Million, Including Record $59.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-ADCETRIS 2015 U.S. and Canada Net Sales Guidance Increased to a Range of $218 Million to $223 Million-
-More than Twenty Presentations at ASH Annual Meeting Featuring Data on ADCETRIS, SGN-CD33A and Other Antibody-Drug Conjugate Pipeline Programs-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)--... More
